Medicare Part D plans must cover at least one weight-management GLP-1

Medicare's coverage of GLP-1 drugs for weight loss is changing in 2026 — but the two available accounts of how and when do not line up.

A consumer guide published by the telehealth referral site Telehealth Ally states that the Treat and Reduce Obesity Act (TROA), which it says was signed into law in late 2025, requires every Medicare Part D plan to cover at least one GLP-1 approved for chronic weight management effective April 1, 2026 ^[1]. The Centers for Medicare & Medicaid Services, in its own May 6, 2026 press release, does not mention TROA, an April 1 mandate, or a copay cap tied to a statute. Instead, CMS describes the "Medicare GLP-1 Bridge," a time-limited demonstration that will let eligible Part D enrollees get certain GLP-1 medications for $50 per month from July 1, 2026 through December 31, 2027 ^[2].

What each source says

According to the guide, the monthly copay for covered anti-obesity medications is capped at $50 regardless of plan, those drugs are exempt from the Part D deductible, and the standard $2,000 annual out-of-pocket cap still applies ^[1]. It also says CMS estimated the new benefit would raise Part D premiums by about $2 to $7 a month ^[1]. That premium estimate does not appear in the CMS press release ^[2].

The guide lists the drugs it says qualify: Wegovy (injectable semaglutide), oral Wegovy (semaglutide), and Zepbound (tirzepatide) ^[1]. It says Ozempic (semaglutide), Mounjaro (tirzepatide), and Rybelsus (oral semaglutide) are not covered for weight loss because they are FDA-approved for type 2 diabetes, though Medicare still covers Ozempic for diabetes ^[1]. Compounded semaglutide and tirzepatide are not covered either, which the guide notes means patients using compounding-focused telehealth companies would have to switch to a brand-name product to use the benefit ^[1].

CMS's release names no specific drugs or brands. It says only that eligible Part D enrollees "may be eligible to access certain GLP-1 medications at $50 for a monthly supply" beginning July 1, and that the agency runs centralized claims adjudication and payment to pharmacies ^[2]. CMS Administrator Dr. Mehmet Oz said the program "changes that by making these medications more affordable and accessible" for seniors who cannot afford them ^[2]. Chris Klomp, Director of Medicare, said the demonstration is meant to make access "simpler, more predictable, and more consistent across the Medicare program" ^[2].

The guide describes eligibility criteria it attributes to Part D rules: a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, dyslipidemia, sleep apnea, or cardiovascular disease ^[1]. It says most plans require prior authorization, with typical decisions in one to two weeks, and that some plans may use step therapy — for example, requiring Wegovy before Zepbound ^[1]. Roughly 14 million Medicare beneficiaries with obesity may become eligible, the guide says ^[1]. CMS does not publish eligibility details in its release, saying only that beneficiaries can talk to their doctor and that more information will come as the program begins ^[2].

Why it matters for patients

The financial gap is large. The guide lists monthly cash prices of about $1,349 for injectable Wegovy, about $1,060 for Zepbound, and about $499 for oral Wegovy, against a capped $50 copay ^[1]. For anyone on Medicare who has been paying out of pocket, that difference is the whole story.

But the conflicting timelines matter too. The only official document here — CMS's press release — points to July 1, 2026, and frames the $50 price as a demonstration that expires at the end of 2027, not a permanent benefit ^[2]. Whether an April 1 formulary mandate exists alongside it is not confirmed by CMS in these sources. The guide itself carries a disclosure that it may receive referral fees and advises verifying details with your own Part D plan ^[1].

What happens next

• May 6, 2026: CMS announces the Medicare GLP-1 Bridge ^[2].
• July 1, 2026: The Bridge $50 monthly price takes effect ^[2]. The guide also says a voluntary CMS program called BALANCE, adding dietitian and behavioral support, is scheduled for the same month, with a participating-provider list expected at launch ^[1].
• December 31, 2027: The Bridge demonstration is scheduled to end ^[2]. What follows is not yet known.